A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder

BACKGROUND: A 12-month, open-label extension study assessed the long-term safety and tolerability of lisdexamfetamine dimesylate (LDX) in adults with binge eating disorder (BED). METHODS: Adults (aged 18–55 y) with BED who completed 1 of 3 antecedent studies were enrolled in a 52-week, open-label ex...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Psychopharmacol
Autores principales: Gasior, Maria, Hudson, James, Quintero, Javier, Ferreira-Cornwell, M. Celeste, Radewonuk, Jana, McElroy, Susan L.
Formato: Artigo
Lenguaje:Inglês
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Contributions
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400413/
https://ncbi.nlm.nih.gov/pubmed/28383364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000000702
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares